Wall Street brokerages expect that Genocea Biosciences, Inc. (NASDAQ:GNCA) will report earnings per share (EPS) of ($0.46) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Genocea Biosciences’ earnings. Genocea Biosciences posted earnings per share of ($0.56) during the same quarter last year, which would indicate a positive year-over-year growth rate of 17.9%. The business is expected to announce its next earnings report on Thursday, February 15th.
According to Zacks, analysts expect that Genocea Biosciences will report full-year earnings of ($2.01) per share for the current fiscal year. For the next year, analysts forecast that the firm will report earnings of ($1.22) per share, with EPS estimates ranging from ($1.63) to ($0.80). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Genocea Biosciences.
Genocea Biosciences (NASDAQ:GNCA) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.08). During the same quarter in the previous year, the company earned ($0.45) earnings per share.
GNCA has been the topic of several research analyst reports. Zacks Investment Research cut Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. ValuEngine cut Genocea Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Needham & Company LLC raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Monday, July 24th. Cowen and Company reissued an “outperform” rating and issued a $40.00 price objective on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Finally, Stifel Nicolaus cut Genocea Biosciences from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $15.00 to $2.50 in a research note on Monday, September 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. Genocea Biosciences presently has an average rating of “Buy” and a consensus target price of $7.62.
Institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. purchased a new stake in Genocea Biosciences during the first quarter worth $217,000. Ameriprise Financial Inc. lifted its holdings in Genocea Biosciences by 34.1% during the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock worth $121,000 after buying an additional 5,068 shares during the period. OxFORD Asset Management LLP purchased a new stake in Genocea Biosciences during the second quarter worth $204,000. Northpointe Capital LLC lifted its holdings in Genocea Biosciences by 9.6% during the second quarter. Northpointe Capital LLC now owns 1,336,062 shares of the biotechnology company’s stock worth $6,974,000 after buying an additional 117,374 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in Genocea Biosciences during the second quarter worth $100,000. Institutional investors own 57.53% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://stocknewstimes.com/2017/11/23/genocea-biosciences-inc-gnca-expected-to-announce-earnings-of-0-46-per-share.html.
Shares of Genocea Biosciences (NASDAQ:GNCA) traded down $0.16 during trading hours on Tuesday, reaching $1.11. The company had a trading volume of 1,210,958 shares, compared to its average volume of 2,100,000. Genocea Biosciences has a 52 week low of $1.03 and a 52 week high of $7.29. The company has a current ratio of 2.97, a quick ratio of 2.97 and a debt-to-equity ratio of 0.56.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.